KrystalBiotech shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 82.
Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory
2021-04-29T22:16:56-04:00April 29th, 2021|
Related Posts
-
Currencies Miss Emerging-Market Rebound Led by Reform Stories
March 28th, 2024 -
Tesla’s $350 Billion Stock Slump Shreds Investor Expectations
March 28th, 2024 -
Stock market holidays in 2024: US markets are closed on these days
March 28th, 2024